Northern Trust Corp Decreases Position in Twist Bioscience Corporation $TWST

Key Points

• Northern Trust Corp reduced its stake in Twist Bioscience Corporation by 1.7% in Q1, owning 616,864 shares worth approximately $24.22 million as of its latest SEC filing.
• CEO Emily M. Leproust sold 1,678 shares for $60,005 on June 20, while CFO Adam Laponis sold 2,449 shares for $93,429 on July 9, signaling insider selling activity.
• Wall Street analysts have mixed ratings for Twist Bioscience, with price targets ranging from $33.00 to $55.00 and an average rating of "Moderate Buy."

Northern Trust Corp cut its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 1.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 616,864 shares of the company's stock after selling 10,785 shares during the quarter. Northern Trust Corp owned approximately 1.03% of Twist Bioscience worth $24,218,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ARK Investment Management LLC grew its position in shares of Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after acquiring an additional 60,276 shares during the last quarter. Nuveen LLC bought a new stake in Twist Bioscience during the first quarter valued at about $31,960,000. American Century Companies Inc. raised its position in shares of Twist Bioscience by 0.9% during the 1st quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock valued at $29,971,000 after buying an additional 7,054 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in Twist Bioscience by 2.4% in the 1st quarter. New York State Common Retirement Fund now owns 452,750 shares of the company's stock worth $17,775,000 after purchasing an additional 10,761 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $49.40.

Twist Bioscience Trading Up 0.1%

Shares of NASDAQ:TWST traded up $0.02 during trading on Friday, reaching $25.65. The stock had a trading volume of 224,691 shares, compared to its average volume of 1,187,464. Twist Bioscience Corporation has a fifty-two week low of $24.28 and a fifty-two week high of $55.33. The business has a fifty day moving average price of $31.94 and a 200-day moving average price of $35.02. The stock has a market cap of $1.55 billion, a P/E ratio of -17.66 and a beta of 2.31. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the transaction, the chief executive officer directly owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,250 shares of company stock worth $193,852. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.